Inventiva S.A. (IVA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inventiva S.A. (IVA:NASDAQ), powered by AI.

Current Price
$3.58
P/E Ratio
-1.9
Market Cap
667M
Sector
Healthcare
What is the Inventiva S.A. stock price forecast?

Inventiva S.A. is currently trading at $3.58. View real-time AI analysis on Alpha Lenz.

What is Inventiva S.A. insider trading activity?

View the latest insider trading data for Inventiva S.A. on Alpha Lenz.

What is Inventiva S.A.'s P/E ratio?

Inventiva S.A.'s P/E ratio is -1.9.

Inventiva S.A.

NASDAQ · IVA
$3.58-0.18(-4.79%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Inventiva S.A.'s future dividend policy...
Alpha Chat Insight

Inventiva S.A. trades at a P/E of -1.9 (undervalued) with strong ROE of 524.0%.

Ask for details

Company Overview

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. With its research and development headquarters situated in France, the company dedicates its efforts to designing treatments for diseases with significant unmet medical needs, particularly in the fields of oncology, fibrosis, and genetic diseases. A key aspect of Inventiva's strategy involves utilizing its deep expertise in the field of nuclear receptor biology and transcription factors to develop innovative medicines. Inventiva also applies its proprietary technologies to facilitate the discovery of novel candidates through sophisticated screening techniques and biological assays. The company plays a notable role in the pharmaceutical sector, engaging in collaborations with leading global healthcare entities to expedite drug development processes. By advancing promising drug candidates through clinical trials, Inventiva aims to bring transformative therapies to the market, ultimately enhancing patient care and addressing critical health challenges globally. The significance of their work is underscored by the potential impact on treatment paradigms for diseases currently lacking effective therapeutic options.

CEOMr. Andrew Obenshain
SectorHealthcare
IndustryBiotechnology
Employees84

Company Statistics

FY 2025

Profile

$667.27MMarket Cap
$4.48MRevenue
0.00Shares Out
84Employees

Margins

N/AGross
-2835.69%EBITDA
-2964.15%Operating
-7899.02%Pre-Tax
-7899.51%Net

Valuation

-1.88P/E
-23.39P/B
148.84EV/Sales
-4.94EV/EBITDA
-6.35P/FCF

Growth (CAGR)

-28.33%Rev 3Yr
64.51%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-192.21%ROA
523.99%ROE
-173.99%ROIC

Financial Health

$99.31MCash & Cash Equivalents
$178.72MNet Debt
-974.80%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Inventiva S.A. (ticker: IVA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 84 employees. Market cap is $667M.

The current price is $3.58 with a P/E ratio of -1.88x and P/B of -23.39x.

ROE is 523.99% and operating margin is -2964.15%. Annual revenue is $4M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Inventiva S.A. (IVA) Stock Forecast 2026 $3.58 — Price, Financials & Analyst Targets | Alpha Lenz